Passage BIO Inc
For the period ended Dec 31, 2023. Filed Mar 4, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 4, 2024
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | |
|---|---|---|---|---|---|---|
| · · Year Ended | ||||||
| · · December 31, | ||||||
| (in thousands) · · 2023 · · 2022 | ||||||
| Cash flows used in operating activities: · · · · | ||||||
| Net loss | | $(102,062) | | $(136,125) | ||
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | | | | | ||
| Depreciation and amortization | | 3,721 | | 3,679 | ||
| Share‑based compensation | | 10,921 | | 18,954 | ||
| Amortization of premium and discount on marketable securities, net | | | (2,036) | | | 773 |
| Loss on disposal of property and equipment | | 463 | | — | ||
| Impairment of long-lived assets | | | 5,390 | | — | |
| Acquired in‑process research and development | | — | | 3,000 | ||
| Changes in operating assets and liabilities: | | | | | ||
| Prepaid expenses and other current assets, and other assets | | 3,837 | | 2,737 | ||
| Prepaid research and development | | 3,766 | | 1,059 | ||
| Right of use assets and operating lease liabilities | | | (133) | | | 463 |
| Accounts payable | | (2,790) | | (5,412) | ||
| Accrued expenses and other current and noncurrent liabilities | | 659 | | (7,338) | ||
| Net cash provided by (used in) operating activities | | (78,264) | | (118,210) | ||
| Cash flows provided by (used in) investing activities: | | | | | ||
| Purchases of marketable securities | | (129,432) | | (157,835) | ||
| Sales or maturities of marketable securities | | 194,815 | | 188,308 | ||
| Purchases of property and equipment | | (146) | | (2,274) | ||
| Purchases of technology licenses | | — | | (3,000) | ||
| Net cash provided by (used in) investing activities | | 65,237 | | 25,199 | ||
| Cash flows provided by (used in) financing activities: | | | | | ||
| Proceeds from the exercise of stock options | | — | | 129 | ||
| Proceeds from the issuance of common stock under employee stock purchase plan | | | 135 | | | 304 |
| Payments for insurance premium financing | | | — | | | (1,786) |
| Net cash provided by (used in) financing activities | | 135 | | (1,353) | ||
| Net increase (decrease) in cash and cash equivalents | | (12,892) | | (94,364) | ||
| Cash and cash equivalents at beginning of year | | 34,601 | | 128,965 | ||
| Cash and cash equivalents at end of year | | $21,709 | | $34,601 | ||
| Supplemental disclosure of non‑cash investing and financing activities: | | | | | ||
| Unrealized gain (loss) on marketable securities | | $923 | | $(553) | ||
| Property and equipment in accounts payable and accrued expenses and other current liabilities | | $23 | | $114 | ||
| Right of use assets recognized upon the adoption of Topic 842 | | $— | | $(20,375) | ||
| Operating lease liabilities recognized upon the adoption of Topic 842 | | $— | | $27,296 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.